Triple therapy may extend life in aggressive lung cancer
NCT ID NCT06610734
First seen Feb 19, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study tests whether adding an immunotherapy drug (adebrelimab) and low-dose radiation to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer. About 202 adults aged 18-75 who have not had prior treatment for this stage will take part. The main goal is to see if the combination improves overall survival compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGSichuan, China
Contact
Conditions
Explore the condition pages connected to this study.